LIS Technologies Inc

What the company does

LIS Technologies is an early-stage uranium enrichment company focused on developing patented and other proprietary laser-based uranium enrichment technologies for producing enriched uranium. Its proprietary technology encompasses the Condensation Repression Isotope-Selective Laser Activation (CRISLA) process and related processes and systems. Subject to regulatory approvals and the development of commercial-scale operations, the company intends to supply enriched uranium to commercial light-water reactor operators and developers of advanced reactor technologies, including small modular reactors and microreactors.

Use of proceeds

The company intends to use the net proceeds for research and development of its uranium enrichment products and technology, including design optimization, site preparation and construction, test work and scoping studies. It also intends to use the proceeds for marketing, promotion and business development activities and for working capital and general corporate purposes, including regulatory compliance, intellectual property protection, additional employee hires and contractor retainment.

Underwriters

Extracted from S-1/A 0001493152-26-050287, filed Nov 5, 2026 and verified against that filing text.

Key risk factors

• Demand and market risk

  “Our business, financial condition, and results of laser enrichment operations are subject to risks related to variability in demand for LEU and related front-end nuclear fuel cycle services, long and uncertain sales cycles, supply chain integration challenges, and competitive and geopolitical market dynamics, any of which could adversely affect our ability to secure contracts, execute operations, and achieve or maintain revenue or profitability.”

• No revenue and continuing losses

  “We have incurred losses and have not generated any revenue since our inception.”

• Unproven technology

  “We are an early-stage company with a limited operating history and an unproven technology, which increases the risk that we may be unable to successfully develop, commercialize, and scale our technology.”

• Development and funding risk

  “Our development roadmap is based on a series of complex and interdependent phases, and delays, cost overruns, technical challenges, regulatory obstacles, or funding constraints could prevent us from achieving our anticipated milestones, production targets, or commercialization objectives.”

• Regulatory approval risk

  “Our business plan depends on obtaining the NRC license and other regulatory approvals for our planned commercial enrichment facility, and any delay in, failure to obtain, or inability to maintain such license and approvals could materially adversely affect our business.”

• Supply chain risk

  “Disruptions in the supply of uranium mining and milling products, conversion services, fluorine, or UF₆ cylinders could adversely affect our uranium enrichment operations and result in delays, increased costs, or both.”

• Capital requirements

  “We will require substantial additional capital to execute our business plan, which may not be available on acceptable terms, or at all, and our failure to obtain such capital could materially and adversely affect our business and prospects.”

• NANO Nuclear dependence

  “We are dependent on a related party, NANO Nuclear, for certain strategic, technical, and commercial support, and any deterioration in that relationship could materially and adversely affect our business, prospects, and ability to execute our strategy.”